"Antibody responses to SARS-CoV-2 Omicron infection in patients with hematological malignancies: A multicenter, prospective cohort study"

作者全名："Li, Jun; Liu, Yi; Wei, Xia; Liu, Zhanshu; Yang, Zailiang; Liu, Ling; Zhou, Meiyu; Xu, Guofa; Chen, Lanting; Ding, Yao; Lei, Haike; Yang, Zailin; Chen, Shuang; Zhang, Xiaomei; Tang, Yifeng; Fu, Huihui; He, Sanxiu; Guo, Bingling; Liang, Xiping; Zhang, Lingqian; Zhang, Wenjun; Wu, Jing; Wang, Chaoyu; Hu, Chongling; Hu, Renzhi; Luo, Xin; Quan, Xi; Zeng, Chensi; Liang, Shunsi; Liu, Tingting; Lv, Jing; Luo, Qin; Qi, Qin; Xu, Luxiang; Xiong, Yan; Liu, Jueyin; Huang, Dehong; Xiao, Chunyan; Liu, Jun; Yang, Tao; Xiang, Ying; Li, Qiying; Nan, Yingyu; Li, Jieping; Zhang, Yong; Wu, Yongzhong; Liu, Yao"

作者地址："[Li, Jun; Liu, Yi; Ding, Yao; Yang, Zailin; Chen, Shuang; Zhang, Xiaomei; Tang, Yifeng; Fu, Huihui; He, Sanxiu; Guo, Bingling; Liang, Xiping; Zhang, Lingqian; Zhang, Wenjun; Wu, Jing; Wang, Chaoyu; Hu, Chongling; Hu, Renzhi; Luo, Xin; Quan, Xi; Zeng, Chensi; Liang, Shunsi; Liu, Tingting; Lv, Jing; Luo, Qin; Qi, Qin; Xu, Luxiang; Xiong, Yan; Liu, Jueyin; Huang, Dehong; Xiao, Chunyan; Liu, Jun; Yang, Tao; Xiang, Ying; Li, Qiying; Nan, Yingyu; Li, Jieping; Liu, Yao] Chongqing Univ, Dept Hematol Oncol, Canc Hosp, Chongqing, Peoples R China; [Wei, Xia; Zhang, Yong] Chongqing Med Univ, Affiliated Hosp 3, Dept Hematol, Chongqing, Peoples R China; [Liu, Zhanshu; Chen, Lanting] Chongqing Med Univ, Yongchuan Hosp, Dept Hematol, Chongqing, Peoples R China; [Yang, Zailiang; Zhou, Meiyu; Xu, Guofa] Chongqing Univ, Fuling Hosp, Dept Hematol & Med Oncol, Chongqing, Peoples R China; [Liu, Ling] Peoples Hosp Chongqing Liang Jiang New Area, Dept Med Lab, Chongqing, Peoples R China; [Lei, Haike] Chongqing Univ, Canc Hosp, Dept Chongqing Canc Multiom Big Data Applicat Engn, Chongqing, Peoples R China; [Wu, Yongzhong] Chongqing Univ, Canc Hosp, Dept Radiat Oncol, Chongqing, Peoples R China; [Zhang, Yong] 1 Shuanghu Branch Rd, Chongqing 401120, Peoples R China; [Wu, Yongzhong; Liu, Yao] 181 HanYu Rd, Chongqing 400030, Peoples R China"

通信作者："Zhang, Y (通讯作者)，1 Shuanghu Branch Rd, Chongqing 401120, Peoples R China.; Wu, YZ; Liu, Y (通讯作者)，181 HanYu Rd, Chongqing 400030, Peoples R China."

来源：JOURNAL OF MEDICAL VIROLOGY

ESI学科分类：MICROBIOLOGY

WOS号：WOS:001138650800062

JCR分区：Q1

影响因子：6.8

年份：2023

卷号：95

期号：12

开始页：　

结束页：　

文献类型：Article

关键词：antibody responses; COVID-19; hematological malignancies; Omicron; SARS-CoV-2

摘要："Little is known about antibody responses to natural Omicron infection and the risk factors for poor responders in patients with hematological malignancies (HM). We conducted a multicenter, prospective cohort study during the latest Omicron wave in Chongqing, China, aiming to compare the antibody responses, as assessed by IgG levels of anti-receptor binding domain of spike protein (anti-S-RBD), to Omicron infection in the HM cohort (HMC) with healthy control cohort (HCC), and solid cancer cohort (SCC). In addition, we intend to explore the risk factors for poor responders in the HMC. Among the 466 HM patients in this cohort, the seroconversion rate was 92.7%, no statistically difference compared with HCC (98.2%, p = 0.0513) or SCC (100%, p = 0.1363). The median anti-S-RBD IgG titer was 29.9 ng/mL, significantly lower than that of HCC (46.9 ng/mL, p < 0.0001) or SCC (46.2 ng/mL, p < 0.0001). Risk factors associated with nonseroconversion included no COVID-19 vaccination history (odds ratio [OR] = 4.58, 95% confidence interval [CI]: 1.75-12.00, p = 0.002), clinical course of COVID-19 <= 7 days (OR = 2.86, 95% CI: 1.31-6.25, p = 0.008) and severe B-cell reduction (0-10/mu L) (OR = 3.22, 95% CI: 1.32-7.88, p = 0.010). Risk factors associated with low anti-S-RBD IgG titer were clinical course of COVID-19 <= 7 days (OR = 2.58, 95% CI: 1.59-4.18, p < 0.001) and severe B-cell reduction (0-10/mu L) (OR = 2.87, 95% CI: 1.57-5.24, p < 0.001). This study reveals a poor antibody responses to Omicron (BA.5.2.48) infection in HM patients and identified risk factors for poor responders. Highlights that HM patients, especially those with these risk factors, may be susceptible to SARS-CoV-2 reinfection, and the postinfection vaccination strategies for these patients should be tailored."

基金机构："Natural Science Foundation of Chongqing, China; Fundamental Research Funds for the Central Universities [2022CDJYGRH-001]; Chongqing Professional Talents Plan [cstc2022ycjh-bgzxm0048]; [CSTB2022NSCQ-MSX1150]"

基金资助正文："The authors thank Prof. Ting Niu (Department of Hematology, West China Hospital, Chengdu, China) for his guidance on study design, registration, and manuscript writing. The authors also would like to extend their deepest gratitude to Prof. Zhian Hu (Department of Physiology, Army Medical University, Chongqing, China) for his guidance on study design and manuscript revision. This study was funded by Natural Science Foundation of Chongqing, China (CSTB2022NSCQ-MSX1150), Fundamental Research Funds for the Central Universities (2022CDJYGRH-001), and Chongqing Professional Talents Plan (cstc2022ycjh-bgzxm0048)."